Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN2 | Q8IZK6 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118454 | 0.89 | ALDH1A1 (0.35) | MCOLN2SMN1; SMN2ALDH1A1EPHX2NPSR1 | |
| SCHEMBL3125363 | 0.87 | MEN1 (0.37) | MCOLN2SMN1; SMN2ALDH1A1EPHX2NPSR1 | |
| SCHEMBL3113106 | 0.80 | ADAMTS4 (0.40) | MCOLN2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL348532 | 0.78 | EPHX2 (0.35) | SMN1; SMN2ALDH1A1EPHX2MEN1TSHR | |
| SCHEMBL3123010 | 0.77 | ALDH1A1 (0.32) | MCOLN2SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL28426483 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1EPHX2MEN1TSHR | |
| SCHEMBL3516005 | 0.75 | EPHX2 (0.34) | EPHX2 | |
| SCHEMBL28432841 | 0.74 | TSHR (0.40) | SMN1; SMN2ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL5115508 | 0.72 | LMNA (0.40) | SMN1; SMN2ALDH1A1NPC1RAB9AEPHX2 | |
| SCHEMBL24126984 | 0.70 | TSHR (0.37) | MCOLN2SMN1; SMN2ALDH1A1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476285-B2 | Purine-core inhibitors of HSP90 and their use in treating cancer | MYREXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-7595401-B2 | Therapeutic compounds and their use in cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016586-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MCL1, TP53, TUBB3 | MCOLN2 2392/4885SMN1; SMN2 1282/4885ALDH1A1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.